ASCO | sciencenewsnet.in

St. Jude pediatric oncologist Dylan Graetz receives Young Investigator Award from ASCO

Dylan Graetz, M.D., M.P.H., a pediatric hematology-oncology fellow at St. Jude, has received a Young Investigator Award from the American Society of Clinical Oncology.

Research Results

Decisions to Stray From Clinical Oncology Pathways Are Often Justified, Roswell Park Analysis Shows

May 29, 2020 sarah Jonas ASCO, Cancer

Clinical oncology pathways are an important tool, helping cancer care providers and their patients to zero in on the most appropriate care plan. But a treating professional’s decision to depart from the recommendations of these decision-support resources may be well-founded and in the patient’s best interests, a new Roswell Park study shows.

Research Results

Targeted Drugs and Immunotherapies May Lower Risk of Therapy-Related Hematologic Cancers

May 29, 2020 sarah Jonas AML acute myeloid leukemia, ASCO, checkpoint inhibitor, Hematologic Cancers, Immunomodulators, Immunotheapy, Multiple Myeloma

While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches. In a study to be presented at the American Society of Clinical Oncology (ASCO) 2020 virtual meeting, a Roswell Park Comprehensive Cancer Center team reports that in many cases, these newer treatment approaches may reduce the risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) compared to chemotherapy-based treatment strategies.

Research Results

Study reveals factors influencing outcomes in advanced kidney cancer treated with immunotherapy

May 29, 2020 sarah Jonas ASCO, Dana-Farber, Dana-Farber Cancer Institute, Immunotherapy, Kidney Cancer, Nature Medicine

By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.

Announcement

Ronald Chen elected as Fellow to American Society of Clinical Oncology

April 28, 2020 sarah Jonas ASCO, Fellow, Radiation Oncologist

Ronald Chen, MD, MPH, has been named a Fellow of the American Society of Clinical Oncology (FASCO) in honor of his extraordinary volunteer service, dedication and commitment to ASCO.

Policy

Alleviating Confusion around Pain Management Recommendations

April 7, 2020 sarah Jonas ASCO, Ash, CDC, FDA, NCCN, Pain Managament

New information from NCCN, ASCO, ASH, CDC, FDA, and others seeks to provide clear guidance on how to optimally manage cancer-related pain without exacerbating the ongoing opioid crisis—published jointly in the Journal of the National Comprehensive Cancer Network and JCO Oncology Practice.